Skip to content
HowShorted

Cidara Therapeutics, Inc. short interest in 2022

In 2022, Cidara Therapeutics, Inc.'s disclosed short interest ran from 0.82% of shares outstanding on 14 Jan 2022 to 0.79% on 30 Dec 2022, a change of -0.03 percentage points. The year's high was 1.22% on 29 Jul 2022 and its low 0.58% on 14 Oct 2022, averaging 0.82% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.73 days on 29 Apr 2022. Full history: Cidara Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Cidara Therapeutics, Inc. in 2022

2022 in figures

Start of year
0.82% (14 Jan 2022)
End of year
0.79% (30 Dec 2022)
Change
-0.03 pp
High
1.22% (29 Jul 2022)
Low
0.58% (14 Oct 2022)
Average
0.82%
Highest days to cover
2.73 (29 Apr 2022)
SEC filings marked
8

Every report in 2022

Cidara Therapeutics, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20220.82%1.03
31 Jan 20221.03%1.74
15 Feb 20220.89%2.42
28 Feb 20220.80%2.68
15 Mar 20220.75%2.5210-K filed, results (8-K)
31 Mar 20220.77%1.48
14 Apr 20220.83%2.72
29 Apr 20220.93%2.73
13 May 20220.77%1.4110-Q filed, results (8-K)
31 May 20220.92%2.22
15 Jun 20220.80%1.51
30 Jun 20220.67%1.46
15 Jul 20220.78%1.39
29 Jul 20221.22%1.00
15 Aug 20220.62%1.0010-Q filed, results (8-K)
31 Aug 20220.86%2.08
15 Sep 20220.85%2.68
30 Sep 20220.65%2.11
14 Oct 20220.58%1.85
31 Oct 20220.69%2.36
15 Nov 20221.01%2.5810-Q filed, results (8-K)
30 Nov 20220.76%1.96
15 Dec 20220.85%1.70
30 Dec 20220.79%1.26

See also: Cidara Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.